Filing Flows

Filing Flows › Health Care › Aytu Biopharma (AYTU)

Aytu Biopharma (AYTU) earnings and revenue breakdown

Latest: Q4 FY26 · 10-K filed Sep 22, 2026 · Aytu Biopharma (AYTU) Q4 FY26 earnings results →

Q4 FY26 Revenue up 6% year over year to $16.1M · 0¢ of every $1 of revenue lost · operating margin -4.8%

Aytu Biopharma made $16.1M in Q4 FY26 (+6% Y/Y). Operating margin -4.8%, net loss $15K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Sep 22, 2026.

Revenue$16.1M
Year over year+6%
Operating margin-4.8%
Net earnings−$15K
Operating cash flow$4.4M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $16.1M in Q4 FY26, up 6% year over year and up 30% from the previous quarter.

Gross margin was 64.6%, down 3.1 points from Q4 FY25. Operating costs exceeded revenue by $777K, an operating margin of -4.8%. Operating expenses fell 37% while revenue rose 6%. The fastest-growing cost line was Sales & marketing (+28%). The quarter ended with a net loss of $15K, narrower than the previous quarter's $5.6M loss. Non-operating items added $773K, -19325% of pre-tax earnings, so the bottom line overstates operating performance.

Operating cash flow was $4.4M (up 57% year over year). Non-cash charges added back $1.1M of depreciation and amortization and $146K of share-based compensation. Working capital and other items added $3.2M. Capital expenditures of $12K left free cash flow of $4.4M.

Quarterly history

Aytu Biopharma revenue by quarterAytu Biopharma revenue by quarter$16.2MQ2 FY25$18.5MQ3 FY25$15.1MQ4 FY25$13.9MQ1 FY26$15.2MQ2 FY26$12.4MQ3 FY26$16.1MQ4 FY26
Aytu Biopharma net earnings by quarterAytu Biopharma net earnings by quarter$788KQ2 FY25$4.0MQ3 FY25−$19.8MQ4 FY25$2.0MQ1 FY26−$10.6MQ2 FY26−$5.6MQ3 FY26−$15KQ4 FY26
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q4 FY2610-KSep 22, 2026$16.1M+6%-4.8%−$15K$4.4M
Q3 FY2610-QMay 13, 2026$12.4M-33%-32.7%−$5.6M−$4.2M
Q2 FY2610-QFeb 3, 2026$15.2M-6%-13.0%−$10.6M$3.7M
Q1 FY2610-QNov 13, 2025$13.9M-16%-10.8%$2.0M−$618K
Q4 FY2510-KSep 23, 2025$15.1M+4%-50.4%−$19.8M$2.8M
Q3 FY2510-QMay 14, 2025$18.5M+32%13.1%$4.0M−$6.5M
Q2 FY2510-QFeb 12, 2025$16.2M-14%-10.4%$788K$2.9M

Charts

Aytu Biopharma: revenue growth, year over year and quarter over quarterAytu Biopharma: revenue growth, year over year and quarter over quarterY/YQ/Q-14%Q2 FY25+32%+14%Q3 FY25+4%-18%Q4 FY25-16%-8%Q1 FY26-6%+9%Q2 FY26-33%-18%Q3 FY26+6%+30%Q4 FY26
Latest (Q4 FY26): Y/Y +6%, Q/Q +30%.
Aytu Biopharma: where the cash came from (+) and went (−), FY26Aytu Biopharma: where the cash came from (+) and went (−), FY26Net borrowing (+) / repaid (−)−$4.8MCash drawn (+) / kept (−)$4.6MOperating cash flow$3.3MOther financing−$3.0MCapital spending−$29K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Aytu Biopharma: profit against cash, quarter by quarterAytu Biopharma: profit against cash, quarter by quarterNet incomeOperating cash flow$1.5M−$1.2MQ1 FY25$788K$2.9MQ2 FY25$4.0M−$6.5MQ3 FY25−$19.8M$2.8MQ4 FY25$2.0M−$618KQ1 FY26−$10.6M$3.7MQ2 FY26−$5.6M−$4.2MQ3 FY26−$15K$4.4MQ4 FY26
Latest (Q4 FY26): Net income −$15K, Operating cash flow $4.4M.
Aytu Biopharma: diluted shares by fiscal yearAytu Biopharma: diluted shares by fiscal year17MFY211MFY223MFY23
-80.1% since FY21: buybacks shrank the count.
Aytu Biopharma: long-term debt falling due (FY26)Aytu Biopharma: long-term debt falling due (FY26)$1.9M2027$1.9M2028$7.4M2029
Cash $26.3M, short-term investments —, long-term debt $11.0M at 2026-06-30.
Aytu Biopharma in its industry: growth against margin (225 companies, SIC 2834)Aytu Biopharma in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMAYTU (+6%, -5%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Aytu Biopharma

Aytu BioPharma, Inc. (“Aytu,” the “Company,” “we,” “us,” or “our”) is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. We were originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. In March 2021, we changed our name to Aytu BioPharma, Inc. Our common stock trades on the Nasdaq Capital Market LLC (the “Nasdaq”) under the ticker symbol “AYTU.” Our principal office is located at 7900 East Union Avenue, Suite 920, Denver, Colorado 80237, and our telephone number is (720) 437-6580.

In its own words, from its 10-K, filed Sep 22, 2026.

Aytu Biopharma against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +6% against the peers' median +7%. Operating margin: -4.8% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
AYTU Aytu BiopharmaQ4 FY26$16.1M+6%-4.8%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Aytu Biopharma 10-K on SEC EDGAR · CIK 1385818 · Pharmaceutical Preparations

13F: who owns AYTU and who is buying

Largest holders of AYTU (13F)Largest holders of AYTU (13F)Nantahala Capital Management, LLC$4.7MStonepine Capital Management, LLC$2.0MVanguard Group$724KVanguard Capital Management LLC$561KDiadema Partners LP$319KTwo Sigma Investments, LP$226KRenaissance Technologies LLC$225KGeode Capital Management, LLC$201KCitadel Advisors LLC$106KVanguard Fiduciary Trust$101K
Funds' net buying of AYTU by quarter (13F)Funds' net buying of AYTU by quarter (13F)−$2.5M2024-09−$304K2024-12−$5K2025-03$2.0M2025-06$347K2025-09$471K2025-12−$63K2026-03$2.1M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on AYTU

History

Every quarter: Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results

Compare AYTU with

中文版：Aytu Biopharma（AYTU）财报

Español · Français